Fiduciary Alliance LLC Has $3.70 Million Position in Pfizer Inc. $PFE

Fiduciary Alliance LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 46.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 145,263 shares of the biopharmaceutical company’s stock after acquiring an additional 46,043 shares during the period. Fiduciary Alliance LLC’s holdings in Pfizer were worth $3,701,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Pfizer by 1.9% in the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after purchasing an additional 10,198,330 shares in the last quarter. Geode Capital Management LLC raised its position in Pfizer by 1.4% during the second quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock valued at $3,080,552,000 after purchasing an additional 1,820,634 shares in the last quarter. Norges Bank bought a new stake in Pfizer during the second quarter worth $2,270,157,000. Amundi boosted its holdings in shares of Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after purchasing an additional 15,758,846 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Pfizer by 2.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock valued at $1,191,760,000 after acquiring an additional 1,135,457 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on PFE shares. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Citigroup began coverage on Pfizer in a report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price objective on the stock. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a report on Wednesday, November 5th. Wolfe Research set a $24.00 price target on Pfizer and gave the company an “underperform” rating in a research note on Wednesday. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average price target of $28.06.

Pfizer Trading Down 1.9%

NYSE PFE opened at $25.05 on Thursday. The firm has a market capitalization of $142.43 billion, a PE ratio of 14.56 and a beta of 0.46. The business’s 50-day moving average price is $25.09 and its two-hundred day moving average price is $24.82. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio is currently 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.